title: AOT and Long-Term Use of Antipsychotics.
authors.affiliation: Dr. Sharfstein is president and CEO of Sheppard Pratt Health System, Towson, Maryland. Dr. Lieberman is with the Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, New York. Dr. Talbott is with the Department of Psychiatry, University of Maryland School of Medicine, Baltimore.
authors.forename: Steven S
authors.initials: SS
authors.lastname: Sharfstein
authors.affiliation: Dr. Sharfstein is president and CEO of Sheppard Pratt Health System, Towson, Maryland. Dr. Lieberman is with the Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, New York. Dr. Talbott is with the Department of Psychiatry, University of Maryland School of Medicine, Baltimore.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Lieberman
authors.affiliation: Dr. Sharfstein is president and CEO of Sheppard Pratt Health System, Towson, Maryland. Dr. Lieberman is with the Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, New York. Dr. Talbott is with the Department of Psychiatry, University of Maryland School of Medicine, Baltimore.
authors.forename: John A
authors.initials: JA
authors.lastname: Talbott
mesh_terms: D014150:Antipsychotic Agents; D006801:Humans
chemical_list: D014150:Antipsychotic Agents